British consumer healthcare company Haleon has lowered its annual revenue growth outlook after weaker-than-expected demand for cold medicines and a regulatory setback in China.

The company, whose brands include Sensodyne, reported the change on 29 October, citing a milder flu season that reduced demand for some seasonal healthcare products.

The downgrade highlights how seasonal illness patterns can affect pharmaceutical and consumer healthcare businesses, particularly companies selling products used to manage colds, flu symptoms and other common conditions.

Haleon also identified a regulatory issue in China as a factor affecting its outlook. The company’s shares fell sharply following the announcement, reflecting investor concerns about its near-term performance.

The development comes as healthcare companies navigate changing consumer demand, regulatory requirements and competition across international markets.

For the UK health sector, Haleon’s update provides a reminder that demand for over-the-counter medicines can fluctuate from one season to another. However, the company’s financial outlook should not be treated as a direct measure of overall flu activity or NHS demand.

Haleon’s revised forecast will now be closely watched by investors and the wider consumer healthcare industry as the company works through the challenges affecting its business.